Pacira BioSciences, Inc. $PCRX Shares Acquired by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Pacira BioSciences by 4.4%, holding approximately 524,486 shares worth $13,033,000 at the end of the first quarter.
• Pacira BioSciences has received positive shifts in analyst ratings, with five analysts now rating the stock as a "Buy" and a consensus target price set at $30.83.
• Insider activity includes significant share sales by SVP Lauren Riker and Director Marcelo Bigal, indicating potential shifts in ownership confidence within the company.

Charles Schwab Investment Management Inc. increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 4.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 524,486 shares of the company's stock after purchasing an additional 22,282 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.13% of Pacira BioSciences worth $13,033,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PCRX. LPL Financial LLC purchased a new position in shares of Pacira BioSciences during the 4th quarter worth about $251,000. Raymond James Financial Inc. purchased a new position in shares of Pacira BioSciences during the 4th quarter worth about $190,000. Sterling Capital Management LLC boosted its stake in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Pacira BioSciences by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 27,883 shares of the company's stock worth $525,000 after purchasing an additional 1,471 shares during the period. Finally, State of Tennessee Department of Treasury boosted its stake in shares of Pacira BioSciences by 14.2% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,180 shares of the company's stock worth $493,000 after purchasing an additional 3,264 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Down 0.7%

Shares of NASDAQ:PCRX traded down $0.18 during trading hours on Friday, hitting $26.67. The company's stock had a trading volume of 616,350 shares, compared to its average volume of 820,286. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -9.59 and a beta of 0.48. The firm's fifty day moving average price is $23.69 and its 200 day moving average price is $24.57. Pacira BioSciences, Inc. has a 52 week low of $12.61 and a 52 week high of $27.64.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm had revenue of $181.10 million during the quarter, compared to analyst estimates of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. Pacira BioSciences's revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.96 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, research analysts expect that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Insider Activity at Pacira BioSciences

In related news, Director Marcelo Bigal sold 4,912 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the transaction, the director owned 11,393 shares in the company, valued at $269,672.31. The trade was a 30.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president owned 59,564 shares of the company's stock, valued at approximately $1,561,172.44. This trade represents a 8.56% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

PCRX has been the subject of several research reports. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Needham & Company LLC lowered their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Zacks Research raised shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. Finally, Truist Financial raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research report on Friday, July 25th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.83.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.